Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - salmonella typhimurium; thiomersal; aluminium hydroxide gel - parenteral liquid/solution/suspension - salmonella typhimurium vaccine-microbial active 0.0 p; thiomersal mercury other 0.13 mg/ml; aluminium hydroxide gel mineral-aluminium-base other 0.0 p - immunotherapy - horse foal | horse mare (female) | female horse - salmonella typhimurium | vaccine | equine rotavirus

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - botulinim toxin type a, quantity: 100 u - injection, powder for - excipient ingredients: albumin; sodium chloride - botox (botulinum toxin type a) purified neurotoxin complex is indicated for the following therapeutic indications: treatment of overactive bladder with symptoms of urinary incontinence, urgency, and frequency, in adult patients who have an inadequate response to or are intolerant of an anticholinergic medication. treatment of urinary incontinence due to neurogenic detrusor overactivity resulting from a defined neurological illness (such as spinal cord injury or multiple sclerosis) and not controlled adequately by anticholinergic agents. prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine). treatment of strabismus in children and adults.treatment of blepharospasm associated with dystonia, including benign blepharospasm and viith nerve disorders (specifically hemifacial spasm) in patients twelve years and older. treatment of cervical dystonia (spasmodic torticollis). treatment of focal spasticity of the upper and lower limbs, including dynamic equinus foot deformity, due to juvenile cerebral palsy in patients two years and older. treatment of severe primary hyperhidrosis of the axillae. treatment of focal spasticity in adults. treatment of spasmodic dysphonia. botox (botulinum toxin type a) purified neurotoxin complex is indicated for the following cosmetic indications: temporary improvement in the appearance of upper facial rhytides (glabellar lines, crow's feet and forehead lines) in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - botulinim toxin type a, quantity: 200 u - injection, powder for - excipient ingredients: albumin; sodium chloride - botox (botulinum toxin type a) purified neurotoxin complex is indicated for the following therapeutic indications: treatment of overactive bladder with symptoms of urinary incontinence, urgency, and frequency, in adult patients who have an inadequate response to or are intolerant of an anticholinergic medication.,treatment of urinary incontinence due to neurogenic detrusor overactivity resulting from a defined neurological illness (such as spinal cord injury or multiple sclerosis) and not controlled adequately by anticholinergic agents.,prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).,treatment of strabismus in children and adults.,treatment of blepharospasm associated with dystonia, including benign blepharospasm and viith nerve disorders (specifically hemifacial spasm) in patients twelve years and older.,treatment of cervical dystonia (spasmodic torticollis).,treatment of focal spasticity of the upper and lower limbs, including dynamic equinus foot deformity, due to juvenile cerebral palsy in patients two years and older.,treatment of severe primary hyperhidrosis of the axillae.,treatment of focal spasticity in adults.,treatment of spasmodic dysphonia.,botox (botulinum toxin type a) purified neurotoxin complex is indicated for the following cosmetic indications: temporary improvement in the appearance of upper facial rhytides (glabellar lines, crow's feet and forehead lines) in adults. botox (botulinum toxin type a) purified neurotoxin complex in indicated for the following therapeutic indications: treatment of urinary incontinence due to neurogenic detrusor overactivity resulting from a defined neurological illness (such as spinal cord injury or multiple sclerosis) and not controlled adequately by anticholinergic agents. this does not include idiopathic overactive bladder. prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine). treatment of strabismus in children and adults.treatment of blepharospasm associated with dystonia, including benign blepharospasm and vii nerve disorders (specifically hemifacial spasm) in patients twelve years and older. treatment of cervical dystonia (spasmodic torticollis). treatment of focal spasticity of the upper and lower limbs, including dynamic equinas foot deformity, due to juvenile cerebral palsy in patients two years of age and older. treatment of severe primary hyperhidrosis of the axillae. treatment of focal spasticity in adults. treatment of spasmodic dysphonia. botox (botulinum toxin type a) purified neurotoxin complex is indicated for the following cosmetic indications: temporary improvement in the appearance of upper facial rhytides (glabellar lines, crow's feet and forehead lines) in adults. botox (botulinum toxin type a) purified neurotoxin complex in indicated for the following therapeutic indications: - prophylaxis of headaches in adults with chronic migraine (headache on at least 15 days per month of which at least 8 days are with migraine); - treatment of strabismus in children and adults; - treatment of blepharospasm associated with dystonia, including benign blepharospasm and vii nerve disorders (specifically hemifacial spasm) in patients twelve years and over; - treatment of cervical dystonia (spasmodic torticollis); - treatment of focal spasticity of the upper and lower limbs, including dynamic equinus foot deformity, due to juvenile cerebral palsy in patients two years of age and older; - treatment of severe primary hyperhidrosis of the axillae; treatment of focal spasticity in adults. - treatment of spasmodic dysphonia. botox (botulinum toxin type a) purified neurotoxin complex in indicated for the following cosmotic indications: temporary improvement in the appearance of upper facial rhytides (glabellar lines, crow-s feet and forehead lines) in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - haemophilus type b polysaccharide, quantity: 10 microgram; tetanus protein, quantity: 18 microgram - injection, powder for - excipient ingredients: trometamol; sucrose - for use in infants from 2 months to 5 years of age for active immunization against invasive disease caused by the haemophilus influenzae type b.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - hpv type 16 l1 protein, quantity: 20 microgram; hpv type 18 l1 protein, quantity: 20 microgram - injection, suspension - excipient ingredients: monobasic sodium phosphate; aluminium hydroxide hydrate; water for injections; 3-o-desacyl-4'-monophosphoryl lipid a; sodium chloride - cervarix is indicated in females from 10 to 45 years of age for the prevention of persistent infection, premalignant cervical lesions and cervical cancer caused by human papillomavirus types 16 and 18. lmmunogenicity studies have been conducted in females aged 10 to 14 years and 26 to 45 years to link efficacy in females aged 15 to 25 years to other populations (see precautions and clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - botulinim toxin type a, quantity: 50 u - injection, powder for - excipient ingredients: albumin; sodium chloride - botox (botulinum toxin type a) purified neurotoxin complex is indicated for the following therapeutic indications: treatment of overactive bladder with symptoms of urinary incontinence, urgency, and frequency, in adult patients who have an inadequate response to or are intolerant of an anticholinergic medication. treatment of urinary incontinence due to neurogenic detrusor overactivity resulting from a defined neurological illness (such as spinal cord injury or multiple sclerosis) and not controlled adequately by anticholinergic agents. prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine). treatment of strabismus in children and adults.treatment of blepharospasm associated with dystonia, including benign blepharospasm and viith nerve disorders (specifically hemifacial spasm) in patients twelve years and older. treatment of cervical dystonia (spasmodic torticollis). treatment of focal spasticity of the upper and lower limbs, including dynamic equinus foot deformity, due to juvenile cerebral palsy in patients two years and older. treatment of severe primary hyperhidrosis of the axillae. treatment of focal spasticity in adults. treatment of spasmodic dysphonia. botox (botulinum toxin type a) purified neurotoxin complex is indicated for the following cosmetic indications: temporary improvement in the appearance of upper facial rhytides (glabellar lines, crow's feet and forehead lines) in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - tetanus toxoid, quantity: 40 microgram/ml; haemophilus influenza type b polyribose ribitol phosphate, quantity: 20 microgram/ml - injection, powder for - excipient ingredients: water for injections; sodium chloride; lactose - hiberix is indicated for active immunisation against haemophilus influenzae type b infection in children aged from 2 months to 5 years.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - haemophilus type b polysaccharide, quantity: 10 microgram; tetanus protein, quantity: 18 microgram - injection, powder for - excipient ingredients: trometamol; sucrose - for use in infants from 2 months to 5 years of age for active immunization against invasive disease caused by the haemophilus influenzae type b.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - canine parainfluenza; bordetella bronchiseptica; canine adeno virus type 2 - misc. vaccines or anti sera - canine parainfluenza vaccine active 0.0 p; bordetella bronchiseptica vaccine-microbial active 0.0 p; canine adeno virus type 2 vaccine-viral active 0.0 p - immunotherapy - dog - over 8 weeks - bordetella bronchiseptica | canine adenovirus - type 2 | canine parainfluenza | canine cough syndrome | infectious tracheobronchitis

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bioproperties pty. ltd. - salmonella typhimurium - oral solution/suspension - salmonella typhimurium vaccine-microbial active 0.0 undefined - immunotherapy - poultry chicks | turkey poult (young) | chickens | day old chicks | hatchlings | turkeys - day old poults | young turkey - salmonella enteridis | salmonella typhimurium | vaccine | equine rotavirus